|
Name |
Cytochalasin Z8
|
Molecular Formula | C28H35NO5 | |
IUPAC Name* |
(1S,4E,6S,7R,8S,10E,12S,13S,16S,17S)-17-benzyl-7,13-dihydroxy-6,8,14,15-tetramethyl-2-oxa-18-azatricyclo[10.7.0.01,16]nonadeca-4,10,14-triene-3,19-dione
|
|
SMILES |
C[C@H]1C/C=C/[C@H]2[C@@H](C(=C([C@@H]3[C@]2(C(=O)N[C@H]3CC4=CC=CC=C4)OC(=O)/C=C/[C@@H]([C@@H]1O)C)C)C)O
|
|
InChI |
InChI=1S/C28H35NO5/c1-16-9-8-12-21-26(32)19(4)18(3)24-22(15-20-10-6-5-7-11-20)29-27(33)28(21,24)34-23(30)14-13-17(2)25(16)31/h5-8,10-14,16-17,21-22,24-26,31-32H,9,15H2,1-4H3,(H,29,33)/b12-8+,14-13+/t16-,17-,21-,22-,24-,25+,26+,28+/m0/s1
|
|
InChIKey |
JQLNBKBPJIXYBO-YHBIJTCLSA-N
|
|
Synonyms |
Cytochalasin Z8; CHEMBL498454; (1S,4E,6S,7R,8S,10E,12S,13S,16S,17S)-17-Benzyl-7,13-dihydroxy-6,8,14,15-tetramethyl-2-oxa-18-azatricyclo[10.7.0.01,16]nonadeca-4,10,14-triene-3,19-dione; 896133-07-6
|
|
CAS | NA | |
PubChem CID | 11518356 | |
ChEMBL ID | CHEMBL498454 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 465.6 | ALogp: | 3.0 |
HBD: | 3 | HBA: | 5 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 95.9 | Aromatic Rings: | 4 |
Heavy Atoms: | 34 | QED Weighted: | 0.455 |
Caco-2 Permeability: | -5.247 | MDCK Permeability: | 0.00006130 |
Pgp-inhibitor: | 0.126 | Pgp-substrate: | 0.982 |
Human Intestinal Absorption (HIA): | 0.627 | 20% Bioavailability (F20%): | 0.017 |
30% Bioavailability (F30%): | 0.078 |
Blood-Brain-Barrier Penetration (BBB): | 0.693 | Plasma Protein Binding (PPB): | 98.25% |
Volume Distribution (VD): | 1.36 | Fu: | 3.48% |
CYP1A2-inhibitor: | 0.054 | CYP1A2-substrate: | 0.101 |
CYP2C19-inhibitor: | 0.291 | CYP2C19-substrate: | 0.684 |
CYP2C9-inhibitor: | 0.099 | CYP2C9-substrate: | 0.053 |
CYP2D6-inhibitor: | 0.012 | CYP2D6-substrate: | 0.134 |
CYP3A4-inhibitor: | 0.874 | CYP3A4-substrate: | 0.422 |
Clearance (CL): | 8.695 | Half-life (T1/2): | 0.029 |
hERG Blockers: | 0.111 | Human Hepatotoxicity (H-HT): | 0.277 |
Drug-inuced Liver Injury (DILI): | 0.102 | AMES Toxicity: | 0.026 |
Rat Oral Acute Toxicity: | 0.934 | Maximum Recommended Daily Dose: | 0.938 |
Skin Sensitization: | 0.52 | Carcinogencity: | 0.198 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.011 |
Respiratory Toxicity: | 0.977 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002183 | 0.757 | D0V3ZA | 0.254 | ||||
ENC002174 | 0.741 | D09NNH | 0.254 | ||||
ENC004801 | 0.649 | D0SP3D | 0.254 | ||||
ENC005130 | 0.634 | D01TSI | 0.247 | ||||
ENC005129 | 0.634 | D06CWH | 0.237 | ||||
ENC004368 | 0.634 | D0I0DL | 0.235 | ||||
ENC003169 | 0.595 | D0FX2Q | 0.234 | ||||
ENC005134 | 0.580 | D08UMH | 0.233 | ||||
ENC004463 | 0.573 | D08FTG | 0.233 | ||||
ENC004369 | 0.568 | D0T0KA | 0.232 |